119 related articles for article (PubMed ID: 34903225)
41. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
[TBL] [Abstract][Full Text] [Related]
42. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
Salmon-Ceron D; Nahon P; Layese R; Bourcier V; Sogni P; Bani-Sadr F; Audureau E; Merchadou L; Dabis F; Wittkop L; Roudot-Thoraval F;
Hepatology; 2019 Sep; 70(3):939-954. PubMed ID: 30569448
[TBL] [Abstract][Full Text] [Related]
43. Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response.
Toyoda H; Tada T; Yasuda S; Mizuno K; Ito T; Kumada T
Clin Infect Dis; 2020 Mar; 70(6):1208-1214. PubMed ID: 31056696
[TBL] [Abstract][Full Text] [Related]
44. Risk of hepatocellular carcinoma after hepatitis C virus cure.
Luna-Cuadros MA; Chen HW; Hanif H; Ali MJ; Khan MM; Lau DT
World J Gastroenterol; 2022 Jan; 28(1):96-107. PubMed ID: 35125821
[TBL] [Abstract][Full Text] [Related]
45. Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.
Janczewska E; Kołek MF; Lorenc B; Klapaczyński J; Tudrujek-Zdunek M; Sitko M; Mazur W; Zarębska-Michaluk D; Buczyńska I; Dybowska D; Czauż-Andrzejuk A; Berak H; Krygier R; Jaroszewicz J; Citko J; Piekarska A; Dobracka B; Socha Ł; Deroń Z; Laurans Ł; Białkowska-Warzecha J; Tronina O; Adamek B; Tomasiewicz K; Simon K; Pawłowska M; Halota W; Flisiak R
World J Gastroenterol; 2021 May; 27(18):2177-2192. PubMed ID: 34025072
[TBL] [Abstract][Full Text] [Related]
46. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.
Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K
Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807
[TBL] [Abstract][Full Text] [Related]
47. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.
Casado JL; Quereda C; Moreno A; Pérez-Elías MJ; Martí-Belda P; Moreno S
J Viral Hepat; 2013 Dec; 20(12):829-37. PubMed ID: 24304452
[TBL] [Abstract][Full Text] [Related]
48. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
[TBL] [Abstract][Full Text] [Related]
49. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort).
Hsu WF; Tsai PC; Chen CY; Tseng KC; Lai HC; Kuo HT; Hung CH; Tung SY; Wang JH; Chen JJ; Lee PL; Chien RN; Lin CY; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Su WW; Chu CH; Chen CJ; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Huang JF; Dai CY; Chuang WL; Yu ML; Peng CY
J Gastroenterol Hepatol; 2021 Oct; 36(10):2884-2892. PubMed ID: 33963615
[TBL] [Abstract][Full Text] [Related]
50. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
51. Lifestyles Associated with Prognosis After Eradication of Hepatitis C Virus: A Prospective Cohort Study in Japan.
Ohfuji S; Matsuura T; Tamori A; Kubo S; Sasaki S; Kondo K; Ito K; Fukushima W
Dig Dis Sci; 2021 Jun; 66(6):2118-2128. PubMed ID: 32720018
[TBL] [Abstract][Full Text] [Related]
52. Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort.
Calvaruso V; Petta S; Cacciola I; Cabibbo G; Cartabellotta F; Distefano M; Scifo G; Di Rosolini MA; Russello M; Prestileo T; Madonia S; Malizia G; Montineri A; Digiacomo A; Licata A; Benanti F; Bertino G; Enea M; Battaglia S; Squadrito G; Raimondo G; Cammà C; Craxì A; Di Marco V;
J Viral Hepat; 2021 Aug; 28(8):1190-1199. PubMed ID: 33896097
[TBL] [Abstract][Full Text] [Related]
53. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
[TBL] [Abstract][Full Text] [Related]
54. Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients.
Campos-Varela I; Castells L; Esteban JI; Bes M; Rodríguez-Frías F; Sapisochin G; Allende H; Charco R; Esteban R
Transplantation; 2012 Feb; 93(4):450-3. PubMed ID: 22262129
[TBL] [Abstract][Full Text] [Related]
55. Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus.
Tachi Y; Hirai T; Toyoda H; Tada T; Hayashi K; Honda T; Ishigami M; Goto H; Kumada T
PLoS One; 2015; 10(7):e0133515. PubMed ID: 26214180
[TBL] [Abstract][Full Text] [Related]
56. Hepatitis C infection at a tertiary hospital in South Africa: Clinical presentation, non-invasive assessment of liver fibrosis, and response to therapy.
Abuelhassan WB; Gasim GI; Ally R; Menezes C
S Afr Med J; 2020 Aug; 110(9):920-925. PubMed ID: 32880279
[TBL] [Abstract][Full Text] [Related]
57. Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan.
Huang YT; Hsieh YY; Chen WM; Tung SY; Wei KL; Shen CH; Chang KC; Lu CK; Yen CW; Lu SN; Hung CH; Chang TS
BMC Gastroenterol; 2021 Jun; 21(1):259. PubMed ID: 34118889
[TBL] [Abstract][Full Text] [Related]
58. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis.
van der Meer AJ; Maan R; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
J Gastroenterol Hepatol; 2016 Jun; 31(6):1168-76. PubMed ID: 26647353
[TBL] [Abstract][Full Text] [Related]
59. Real life application of FIB-4 & APRI during mass treatment of HCV genotype 4 with directly acting anti-viral agents in Egyptian patients, an observational study.
Said M; Soliman Z; Daebes H; M El-Nahaas S; El-Serafy M
Expert Rev Gastroenterol Hepatol; 2019 Dec; 13(12):1189-1195. PubMed ID: 31702417
[No Abstract] [Full Text] [Related]
60. Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV.
Toyoda H; Tada T; Tachi Y; Hirai T; Yasuda S; Honda T; Hayashi K; Ishigami M; Goto H; Kumada T
Antivir Ther; 2017; 22(3):185-193. PubMed ID: 27586087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
